ARTICLE | Clinical News
NGD 97-1: Began Phase I testing
February 8, 1999 8:00 AM UTC
Neurogen Corp. (NRGN), Branford, Conn. Product: NGD 97-1 Business: Neurological Therapeutic category: Neurotransmission Target: GABA receptors Description: Small molecule GABA receptor modulator Indi...